These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17267215)

  • 1. Oxazolidinones as novel human CCR8 antagonists.
    Jin J; Wang Y; Wang F; Kerns JK; Vinader VM; Hancock AP; Lindon MJ; Stevenson GI; Morrow DM; Rao P; Nguyen C; Barrett VJ; Browning C; Hartmann G; Andrew DP; Sarau HM; Foley JJ; Jurewicz AJ; Fornwald JA; Harker AJ; Moore ML; Rivero RA; Belmonte KE; Connor HE
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1722-5. PubMed ID: 17267215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8.
    Jenkins TJ; Guan B; Dai M; Li G; Lightburn TE; Huang S; Freeze BS; Burdi DF; Jacutin-Porte S; Bennett R; Chen W; Minor C; Ghosh S; Blackburn C; Gigstad KM; Jones M; Kolbeck R; Yin W; Smith S; Cardillo D; Ocain TD; Harriman GC
    J Med Chem; 2007 Feb; 50(3):566-84. PubMed ID: 17266208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).
    Ghosh S; Elder A; Guo J; Mani U; Patane M; Carson K; Ye Q; Bennett R; Chi S; Jenkins T; Guan B; Kolbeck R; Smith S; Zhang C; LaRosa G; Jaffee B; Yang H; Eddy P; Lu C; Uttamsingh V; Horlick R; Harriman G; Flynn D
    J Med Chem; 2006 May; 49(9):2669-72. PubMed ID: 16640325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zwitterionic CRTh2 antagonists.
    Luker T; Bonnert R; Paine SW; Schmidt J; Sargent C; Cook AR; Cook A; Gardiner P; Hill S; Weyman-Jones C; Patel A; Thom S; Thorne P
    J Med Chem; 2011 Mar; 54(6):1779-88. PubMed ID: 21355602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-aminothiazole-gamma-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists.
    Zhou C; Guo L; Parsons WH; Mills SG; MacCoss M; Vicario PP; Zweerink H; Cascieri MA; Springer MS; Yang L
    Bioorg Med Chem Lett; 2007 Jan; 17(2):309-14. PubMed ID: 17092717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.
    Allen DR; Bolt A; Chapman GA; Knight RL; Meissner JW; Owen DA; Watson RJ
    Bioorg Med Chem Lett; 2007 Feb; 17(3):697-701. PubMed ID: 17097877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).
    Bromidge SM; Arban R; Bertani B; Bison S; Borriello M; Cavanni P; Dal Forno G; Di-Fabio R; Donati D; Fontana S; Gianotti M; Gordon LJ; Granci E; Leslie CP; Moccia L; Pasquarello A; Sartori I; Sava A; Watson JM; Worby A; Zonzini L; Zucchelli V
    J Med Chem; 2010 Aug; 53(15):5827-43. PubMed ID: 20590088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program.
    Davenport AJ; Möller C; Heifetz A; Mazanetz MP; Law RJ; Ebneth A; Gemkow MJ
    Assay Drug Dev Technol; 2010 Dec; 8(6):781-9. PubMed ID: 21133680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.
    Yunomae K; Ichisaki S; Matsuo J; Nagayama S; Fukuzaki K; Nagata R; Kito G
    J Appl Toxicol; 2007; 27(1):78-85. PubMed ID: 17146843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Support vector machines classification of hERG liabilities based on atom types.
    Jia L; Sun H
    Bioorg Med Chem; 2008 Jun; 16(11):6252-60. PubMed ID: 18448342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.
    Jin J; Dhanak D; Knight SD; Widdowson K; Aiyar N; Naselsky D; Sarau HM; Foley JJ; Schmidt DB; Bennett CD; Wang B; Warren GL; Moore ML; Keenan RM; Rivero RA; Douglas SA
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3229-32. PubMed ID: 15936190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxadiazoles in medicinal chemistry.
    Boström J; Hogner A; Llinàs A; Wellner E; Plowright AT
    J Med Chem; 2012 Mar; 55(5):1817-30. PubMed ID: 22185670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.
    Procopiou PA; Ancliff RA; Bamford MJ; Browning C; Connor H; Davies S; Fogden YC; Hodgson ST; Holmes DS; Looker BE; Morriss KM; Parr CA; Pickup EA; Sehmi SS; White GV; Watts CJ; Wilson DM; Woodrow MD
    J Med Chem; 2007 Dec; 50(26):6706-17. PubMed ID: 18052318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and in vitro antibacterial activity of novel 3-azabicyclo[3.3.0]octanyl oxazolidinones.
    Bhattarai D; Lee SH; Seo SH; Nam G; Kang SB; Pae AN; Kim EE; Oh T; Cho SN; Keum G
    Chem Biol Drug Des; 2012 Sep; 80(3):388-97. PubMed ID: 22553981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.
    Yang L; Butora G; Jiao RX; Pasternak A; Zhou C; Parsons WH; Mills SG; Vicario PP; Ayala JM; Cascieri MA; MacCoss M
    J Med Chem; 2007 May; 50(11):2609-11. PubMed ID: 17461566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel N-aryl piperazine CXCR4 antagonists.
    Zhao H; Prosser AR; Liotta DC; Wilson LJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4950-4955. PubMed ID: 25935642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propranolol inhibits the human ether-a-go-go-related gene potassium channels.
    Yao X; McIntyre MS; Lang DG; Song IH; Becherer JD; Hashim MA
    Eur J Pharmacol; 2005 Sep; 519(3):208-11. PubMed ID: 16150441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.
    Pinard E; Alanine A; Alberati D; Bender M; Borroni E; Bourdeaux P; Brom V; Burner S; Fischer H; Hainzl D; Halm R; Hauser N; Jolidon S; Lengyel J; Marty HP; Meyer T; Moreau JL; Mory R; Narquizian R; Nettekoven M; Norcross RD; Puellmann B; Schmid P; Schmitt S; Stalder H; Wermuth R; Wettstein JG; Zimmerli D
    J Med Chem; 2010 Jun; 53(12):4603-14. PubMed ID: 20491477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
    Nugiel DA; Krumrine JR; Hill DC; Damewood JR; Bernstein PR; Sobotka-Briner CD; Liu J; Zacco A; Pierson ME
    J Med Chem; 2010 Feb; 53(4):1876-80. PubMed ID: 20088516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.